RxDoctor Payments Data

Ali Shafiq, MD

Cardiovascular Disease · Detroit, MINPI 1609005503

Payments from drug & device makers

$11,693in general payments, 2019–2025

Across 73 payments — averaging $160.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Boston Scientific$2K
  • Baylis Medical Company Inc$2K
  • Edwards Lifesciences$1K
  • W. L. Gore & Associates, Inc.$1K
  • Abbott$482
  • plus $529 from 5 others

What the payments were for

  • Travel & lodging$9,42681%
  • Food & beverage$2,12718%
  • Education$1401%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,693 in reported general payments places this provider in the 70th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$108,684
Medicare patients
478
Services billed
1,136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban126$133,415
Repatha SureclickEvolocumab80$111,823
EntrestoSacubitril/Valsartan53$65,675
JardianceEmpagliflozin39$51,648
XareltoRivaroxaban37$44,739
Praluent PenAlirocumab22$30,438
BrilintaTicagrelor32$27,369
Metoprolol Succinate325$3,745
Atorvastatin Calcium278$1,767
FenofibrateFenofibrate Nanocrystallized56$1,609
Ezetimibe84$1,490
Isosorbide Mononitrate ErIsosorbide Mononitrate92$998
Lisinopril158$951
Rosuvastatin Calcium116$940
ClopidogrelClopidogrel Bisulfate95$876

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$29$65,67553 claims
Johnson & JohnsonXarelto$24$44,73937 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →